FMP
Tricida, Inc.
TCDA
NASDAQ
Inactive Equity
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
0.108 USD
0 (0%)
About
ceo
Dr. Gerrit Klaerner Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.tricida.com
exchange
NASDAQ
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
CIK
0001595585
ISIN
US89610F1012
CUSIP
89610F101
Address
7000 Shoreline Court
Phone
415 429 7800
Country
US
Employee
57
IPO Date
Jun 28, 2018
Summary
CIK
0001595585
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
89610F101
ISIN
US89610F1012
Country
US
Price
0.11
Beta
0
Volume Avg.
12.58M
Market Cap
5.95M
Shares
-
52-Week
0.0411-13.85
DCF
11.3
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.02
P/B
-
Website
https://www.tricida.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TCDA News
It looks like there's no news available.
